Do GLP-1-based therapies increase cancer risk?

Diabetes Care. 2013 Aug;36 Suppl 2(Suppl 2):S245-52. doi: 10.2337/dcS13-2004.

Authors

Michael A Nauck¹, Nele Friedrich

Affiliation

¹ Diabeteszentrum Bad Lauterberg, Bad Lauterberg, Harz, Germany. michael.nauck@diabeteszentrum.de

No abstract available

Publication types

Review

MeSH terms

Animals
Drug Therapy, Combination
Drug-Related Side Effects and Adverse Reactions / epidemiology
Drug-Related Side Effects and Adverse Reactions / etiology
Glucagon-Like Peptide 1 / administration & dosage
Glucagon-Like Peptide 1 / adverse effects*
Humans
Hypoglycemic Agents / administration & dosage
Hypoglycemic Agents / adverse effects*
Pancreatic Neoplasms / epidemiology*
Pancreatitis / epidemiology
Pancreatitis / etiology
Risk Factors
Thyroid Neoplasms / epidemiology*

Substances

Hypoglycemic Agents
Glucagon-Like Peptide 1